Clinical trial registry record

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 28, 2017.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02205333
Last registry update
June 28, 2017
Status
Terminated
Phase
Phase 1, Phase 2
Enrollment
48
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
INTERVENTIONAL
Evidence population
Human clinical study registration
Participants
48
Population
Not reported
Duration
Not reported
Intervention
MEDI6469 Monotherapy; MEDI6469 Plus Tremelimumab; MEDI6469 Plus Durvalumab; MEDI6469 plus Rituximab
Comparator
Not reported
Outcomes measured
Not reported
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. It cannot show whether an intervention worked or was safe.

Safety and approvalNot reported Not reported

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Immune-age biomarkers · 60%Title contains controlled term: immune age. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

immune age biomarkers
Read the original source →